SRPT Lost 39% In A Month. Past Slides Turned Into Crashes.
- In Dot-Com Bubble, Sarepta Therapeutics stock declined 89% vs 37% for S&P 500. During global financial crisis, it dropped 85% compared to the S&P 500’s 57%.
- Following the Inflation Shock, the stock has not yet recovered to its pre-crisis peak, whereas the S&P 500 recovered in 15 months. In the dot-com bubble, the stock took 213 months to recover, compared to 69 months for the S&P 500.
Sarepta Therapeutics Stock Performance In Market Crashes:
| SRPT | S&P 500 | |
|---|---|---|
| Dot-Com Bubble | ||
| % Change from Pre-Recession Peak | -89% | -37% |
| # of Months for Full Recovery | 213 | 69 |
| Global Financial Crisis | ||
| % Change from Pre-Recession Peak | -85% | -57% |
| # of Months for Full Recovery | 46 | 49 |
| 2018 Correction | ||
| % Change from Pre-Recession Peak | -55% | -20% |
| # of Months for Full Recovery | 9 | 4 |
| Covid Pandemic | ||
| % Change from Pre-Recession Peak | -55% | -34% |
| # of Months for Full Recovery | 9 | 5 |
| Inflation Shock | ||
| % Change from Pre-Recession Peak | -63% | -25% |
| # of Months for Full Recovery | Yet to Recover | 15 |
Worried that SRPT is yet to hit the bottom? You could take a look at the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.
Relevant Articles